VACC News and Press, Vaccitech plc From 11/11/22

Vaccitech press release ( NASDAQ: VACC ): Q3 GAAP EPS of $0.22. Revenue of $6.17M. As of September 30, 2022, cash and cash equivalents were $200.1 million, compared to $214.1 million as of December 31, 2021. For further details see: Vaccitech GAAP EPS of $0.2...

OXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharma...

OXFORD, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune d...

VTP-300 induced sustained reductions of hepatitis B surface antigen in people with chronic hepatitis B during ongoing, fully enrolled Phase 1b/2a trial. VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab demonstrated no treatment-relat...

OXFORD, United Kingdom, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company will be presenting an update on its Phase 1b...

OXFORD, United Kingdom, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the dosing of the first patients in HBV003. HBV003 is a Phase...

Vaccitech ( NASDAQ: VACC ) is trading ~4.2% higher after preclinical data showed that that intravenous administration of SNAPvax vaccine to treat cancer reverses suppression in the tumor microenvironment. The company said SNAPvax co-delivered tumor antige...

Vaccitech collaborators at NIH’s Vaccine Research Center demonstrate that IV administration of SNAPvax in animal models activates two key pathways leading to improved T cell mediated tumor killing in a paradigm referred to as “ VAX-INNATE ” VAX...

OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Scientific Officer, Dr. Thoma...

Vaccitech ( NASDAQ: VACC ) said Tuesday it promoted Gemma Brown to the CFO role, succeeding Georgy Egorov. Brown joined VACC as head of financial reporting in 2021, before her promotion to CFO. For further details see: Vaccitech promotes Gemma Brown to CFO ...